Melanoma in name. Unique in biology.
Though they share a name, uveal melanoma is biologically distinct from cutaneous melanoma, with differences in molecular drivers.1,2
A significant
unmet need
Despite advances in oncology, patients with metastatic uveal melanoma continue to have limited therapeutic options for this rare, often aggressive malignancy.2-4
Stay informed on metastatic uveal melanoma advances
Advancement begins with changing how we see and treat metastatic uveal melanoma. Learn more about uveal melanoma advances that target core oncogenic drivers.
1. Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743. doi:10.1101/gad.296962.117
2. Koch EAT, Heppt MV, Berking C. The current state of systemic therapy of metastatic uveal melanoma. Am J Clin Dermatol. 2024;25(5):691-700. doi:10.1007/s40257-024-00872-1
3. Hanratty K, Finegan G, Rochfort KD, Kennedy S. Current treatment of uveal melanoma. Cancers (Basel). 2025;17(9):1403. doi:10.3390/cancers17091403
4. Ziogas DC, Foteinou D, Theocharopoulos C, et al. State‑of‑the‑art in metastatic uveal melanoma treatment: a 2025 update. Curr Oncol Rep. 2025;27(7):803-821. doi:10.1007/s11912-025-01684-0